According to the Complaint, Cocrystal Pharma, Inc. ("Cocrystal", f/k/a/ BioZone Pharmaceuticals, Inc.) is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.

The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price; (2) this illicit scheme would result in governmental scrutiny, including from the SEC; (3) Defendants failed to abide by SEC disclosure regulations; and (4) as a result, Defendants’ statements about Cocrystal’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On April 9, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on June 25.

On July 16, 2020, the parties notified the Court that they had reached a Settlement in principle. On August 17, the parties entered into a Stipulation and Agreement of Settlement. The Court granted preliminary approval of the Settlement on August 18. On December 16, the Court granted final approval of the Settlement and entered Final Judgment. The Court issued an Order granting Plaintiffs' motion for distribution of class action settlement funds on September 1, 2021.